DataMeds AI agrees to exchange 9.9% stakes with DiaGen AI
AGPU•DataMeds AI and DiaGen AI agreed to exchange shares representing 9.9% stakes in each company. The cancer target discovery and drug development partnership has an expected total value of $1.5 million in cash and in-kind contributions through project milestones.
1. Share exchange and partnership
DataMeds AI will issue 630,000 common shares to DiaGen AI, representing 9.9% of its common shares outstanding on the agreement date. In exchange, DiaGen AI will issue DataMeds AI 9.9% of its fully diluted common shares outstanding. The exchange supports a cancer target discovery and drug development partnership between DataMeds AI subsidiary Helomics and DiaGen AI.
2. Project funding
The transaction has an expected total value of $1.5 million in cash and in-kind contributions through project milestones. DataMeds AI will cover up to 50% of compute expenses, while DiaGen AI will fund wet-lab hard costs tied to milestones.




